SNCA and Parkinson disease: Using an ultra-sensitive IMR assay [19,20,21], which could quantitatively detect pS129-α-synuclein at ultra-low concentrations in plasma, our findings support the potential utility of plasma phosphorylated α-synuclein as a disease marker for PD.